Filing Flows › Beam Therapeutics (BEAM) › Q2 2026
Beam Therapeutics (BEAM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Beam Therapeutics (BEAM) reported revenue of $490K for the second quarter 2026 (Q2 2026), -94% from a year earlier and -98% from the quarter before.
Beam Therapeutics, Q2 2026: revenue $490K (-94% year over year), net loss $123M, operating cash flow −$66.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $490K | -98% | -94% |
| Operating profit | −$127M | — | — |
| Net earnings | −$123M | — | — |
| Operating cash flow | −$66.1M | — | — |
What changed
Revenue was $490K in Q2 2026, down 94% year over year and down 98% from the previous quarter.
Operating costs exceeded revenue by $126.6M, an operating margin of -25827.1%. Total costs fell 1% while revenue fell 94%. The fastest-growing cost line was General & admin (+19%). The quarter ended with a net loss of $122.7M, wider than the previous quarter's $94.3M loss.
Operating cash flow was −$66.1M. Non-cash charges added back $5.4M of depreciation and $19.3M of share-based compensation. Working capital and other items added $31.9M. Capital expenditures of $2.4M exceeded it, leaving free cash flow of −$68.5M.
Questions
What was Beam Therapeutics' revenue in the second quarter 2026?
Beam Therapeutics (BEAM) reported revenue of $490K for the second quarter 2026 (Q2 2026), -94% from a year earlier and -98% from the quarter before.
Source: Beam Therapeutics 10-Q on SEC EDGAR.